AllVascular is an Australian medical device company based in Sydney. The Company’s lead product is a novel vascular access system called the AVAS®. The AVAS® is unique as it can facilitate treatments that require frequent vascular access such as the delivery of anti cancer agents to treat solid organ cancers. For this type of treatment, the AVAS® enables the targeting of anti-cancer agents, such as chemotherapy, in isolation, directly to cancerous organ. The aim of this method is to reduce side effects of the anti-cancer agents whilst increasing effectiveness.
In 2019 the AVAS® was granted CE and TGA approval enabling it to be sold into Australia and Europe.
